PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
AID  - 10.1136/jitc-2020-000891corr1
DP  - 2021 May 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e000891corr1
VI  - 9
IP  - 5
4099  - http://jitc.bmj.com/content/9/5/e000891corr1.short
4100  - http://jitc.bmj.com/content/9/5/e000891corr1.full
SO  - J Immunother Cancer2021 May 01; 9